Variability in Vedolizumab Exposure Between Patients With Inflammatory Bowel Disease

被引：0
|
作者：
Gils, Ann
Dreesen, Erwin
Peeters, Miet
Brouwers, Els
Ferrante, Marc
Van Assche, Gert
Vermeire, Severine
机构：
来源：
GASTROENTEROLOGY | 2016年 / 150卷 / 04期
关键词：
D O I：
10.1016/S0016-5085(16)31431-7
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Sa1943
引用
收藏
页码：S411 / S412
页数：2
相关论文
共 50 条
  • [41] Transitioning from Intravenous to Subcutaneous Vedolizumab in Patients with Inflammatory Bowel Disease [TRAVELESS]
    Ventress, Esther
    Young, David
    Rahmany, Sohail
    Harris, Clare
    Bettey, Marion
    Smith, Trevor
    Moyses, Helen
    Lech, Magdalena
    Gwiggner, Markus
    Felwick, Richard
    Cummings, J. R. Fraser
    [J]. JOURNAL OF CROHNS & COLITIS, 2022, 16 (06): : 911 - 921
  • [42] Early experience with therapeutic drug monitoring of vedolizumab in patients with inflammatory bowel disease
    Fernandez, R.
    Sanchez, G.
    Pedraza, L.
    Prieto, V.
    Calabuig, V. K.
    Fernandez, E.
    Otero, M. J.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (01) : 361 - 362
  • [43] EVALUATING THE IMPACT OF VEDOLIZUMAB ON POSTOPERATIVE COMPLICATIONS IN INFLAMMATORY BOWEL DISEASE PATIENTS.
    Ayoub, F.
    Ewelukwa, O.
    Brar, T.
    Forde, J.
    Mramba, L.
    Glover, S.
    Iqbal, A.
    Tan, S.
    [J]. DISEASES OF THE COLON & RECTUM, 2018, 61 (05) : E141 - E141
  • [44] Endoscopic and Histologic Response and Remission in Inflammatory Bowel Disease Patients Initiating Vedolizumab
    Christensen, Britt
    Rubin, David T.
    Goeppinger, Sarah
    Colman, Ruben J.
    Yarur, Andres
    Hirsch, Ayal
    Bocheneck, Ashley
    Wichmann, Alana
    Sakuraba, Atsushi
    Cohen, Russell
    Siddiqui, Dania
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 : S783 - S784
  • [45] Long-term Clinical Experience with Vedolizumab in Patients with Inflammatory Bowel Disease
    Parikh, Asit
    Fox, Irving
    Leach, Timothy
    Xu, Jing
    Scholz, Catherine
    Patella, Michael
    Feagan, Brian G.
    [J]. INFLAMMATORY BOWEL DISEASES, 2013, 19 (08) : 1691 - 1699
  • [46] VEDOLIZUMAB INDUCES DE NOVO EXTRAINTESTINAL MANIFESTATIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Kim, Su Bin
    Diaz, Liege I.
    Calmet, Fernando
    Quintero, Maria A.
    Schwartz, Ingrid
    Abreu, Maria T.
    [J]. GASTROENTEROLOGY, 2018, 154 (06) : S360 - S360
  • [47] Vedolizumab Drug Levels During Maintenance Therapy in Inflammatory Bowel Disease Patients
    Koduru, Pramoda
    Morrill, Amanda
    Abraham, Bincy
    [J]. INFLAMMATORY BOWEL DISEASES, 2017, 23 : S63 - S64
  • [48] Vedolizumab trough concentrations are associated with endoscopic response in patients with inflammatory bowel disease
    Chao, C. -Y.
    Restellini, S.
    Lemieux, C.
    Germain, P.
    Bitton, A.
    Lakatos, P. L.
    Wild, G.
    Seidman, E.
    Bessissow, T.
    Afif, W.
    [J]. JOURNAL OF CROHNS & COLITIS, 2018, 12 : S367 - S368
  • [49] The Risk of Tuberculosis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab in Korea
    Choi, Myeong Geun
    Ye, Byong Duk
    Yang, Suk-Kyun
    Shim, Tae Sun
    Jo, Kyung-Wook
    Park, Sang Hyoung
    [J]. JOURNAL OF KOREAN MEDICAL SCIENCE, 2022, 37 (14)
  • [50] PREDICTORS OF ACUTE AND DELAYED VEDOLIZUMAB INFUSION REACTIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Gold, Stephanie
    Cohen-Mekelburg, Shirley A.
    Schneider, Yecheskel
    Bosworth, Brian P.
    Steinlauf, Adam F.
    Scherl, Ellen
    [J]. GASTROENTEROLOGY, 2018, 154 (06) : S368 - S368
12345